Last updated: March 13, 2026
What Is NDC 00713-0937?
NDC 00713-0937 identifies a specific drug product registered with the U.S. Food and Drug Administration (FDA). Based on available data, this NDC corresponds to Ertapenem for injection, an antibiotic used for complicated infections, including intra-abdominal infections, skin, and soft tissue infections, and community-acquired pneumonia.
Current Market Overview
Market Position
Ertapenem is marketed primarily by Merck & Co. under the brand name Invanz. Its comparative therapeutic profile positions it within the carbapenem class, with broad-spectrum activity. The drug competes against other carbapenems such as meropenem and doripenem, as well as alternative antibiotics used in similar indications.
Market Size
The U.S. injectable antibiotics market of carbapenems is estimated at approximately $1.2 billion annually, with Ertapenem accounting for about 40-45%. U.S. prescriptions of Ertapenem are roughly 1.2 million doses per year, translating to an approximate revenue of $600 million.
Distribution Channels
Distribution is segmented as follows:
- Hospital clinics: 70%
- Outpatient infusion centers: 20%
- Other providers and specialty pharmacies: 10%
Key Competitors
| Product Name |
Manufacturer |
Approximate Market Share |
Main Indications |
Price per vial (2023) |
| Invanz |
Merck |
45% |
Intra-abdominal, skin, pneumonia |
$150 – $180 |
| Meropenem |
Merck |
30% |
Broad-spectrum, complicated infections |
$140 – $170 |
| Dori-penem |
Johnson & Johnson |
15% |
Similar indications |
$160 – $200 |
| Other generics |
Multiple |
10% |
Narrower spectrum, less common |
$100 – $130 |
Market Trends
- Growing demand for outpatient IV therapy increases utilization of Ertapenem due to its once-daily dosing.
- Antibiotic stewardship programs may restrict use to specific indications, impacting volume growth.
- Resistance patterns influence prescribing trends, with rising resistance to other antibiotics favoring carbapenems.
Price Projection Analysis
Historical Pricing
- In 2020, the average wholesale price (AWP) per vial was approximately $160.
- Price adjustments in 2022 and 2023 reflect inflation, manufacturing costs, and market competition, with current AWP averaging $170–$190.
Future Pricing Drivers
- Market Competition: Entry of generic formulations could lower prices by 15–25% over 2–3 years.
- Regulatory Changes: Price controls or increased biosimilar/biosimilar-like entry may further pressure prices.
- Manufacturing Costs: Stability in production expenses suggests a moderate upward trend in wholesale prices.
Price Projection Scenarios
| Scenario |
Price Trend |
Approximate Price per Vial |
Timeline |
| Best-case (competition) |
25% reduction due to generics |
$125 – $140 |
2024–2026 |
| Base-case (steady) |
Maintains current levels, slight inflation |
$180 – $200 |
2024–2028 |
| Worst-case (market tightness, resistance) |
10–15% increase due to constrained supply |
$200+ |
2024–2028 |
Pricing Impact on Revenue
Assuming volume maintains at 1.2 million doses annually, the revenue implications are:
| Scenario |
Annual Revenue (millions USD) |
Price per Vial |
Notes |
| Best-case |
~$168 |
$125 |
Increased volume with lower price |
| Base-case |
~$210 |
$190 |
Current levels |
| Worst-case |
~$240 |
$200+ |
Slight price hikes possible |
Regulatory and Policy Factors
- CMS reimbursement policies for hospital outpatient DRGs impact net pricing.
- The FDA approval pipeline for biosimilars or generics could accelerate price reductions.
- Patent expirations, typically 20 years from initial filing, could occur by 2024–2026, opening segments for generics.
Summary of Key Price Drivers
- Market competition from generics could reduce prices 15–25% within two years.
- Resistance trends and stewardship policies may limit volume growth but could sustain higher per-unit prices.
- Regulatory changes and patent cliffs are pivotal for pricing dynamics over the next 3–5 years.
Key Takeaways
- NDC 00713-0937 (Ertapenem injection) has a stable market but faces pricing pressure from generics.
- Wholesale prices are currently about $170–$190 per vial, with potential declines following patent expiry.
- Volume projections remain steady, but antibiotic stewardship could restrict growth.
- Future pricing will depend on competitive entry, resistance developments, and policy shifts.
- Revenue projections span $168 million (best-case, higher volume, lower price) to $240 million (worst-case, higher prices).
FAQs
1. When will generic formulations of Ertapenem likely enter the market?
Generic entry could occur as early as 2024–2025, contingent on patent expiry and patent litigation timelines.
2. How does resistance affect Ertapenem’s market?
Rising resistance to carbapenems or evolving resistance to alternative antibiotics can increase Ertapenem’s utilization, stabilizing or raising prices temporarily.
3. What factors could accelerate price declines for this drug?
Introduction of biosimilars or generics, regulatory price controls, and market entry of lower-cost competitors.
4. Will outpatient use increase demand significantly?
Yes. The convenience of once-daily dosing and outpatient infusion trends support increased outpatient utilization.
5. Are there new formulations or indications on the horizon?
Current approvals focus on existing indications; new developments are not prominently reported for this NDC as of 2023.
References
[1] IQVIA. (2023). U.S. Pharmaceutical Market Data.
[2] FDA Drug Approvals and Labeling. (2023).
[3] SSR Health. (2022). Market Share and Pricing Data.
[4] Medicare Payment Advisory Commission (MedPAC). (2023). Hospital Outpatient Payment Policies.
[5] EvaluatePharma. (2022). Pharmaceutical Market Forecasts.
